REGEN BIOLOGICS, INC. Warrant to Purchase Common Stock Date of Issue: October 1, 2003Warrant Agreement • March 27th, 2008 • Regen Biologics Inc • Surgical & medical instruments & apparatus • Delaware
If the Common Stock of the Company is traded regularly in a public market, the fair market value of a share of Common Stock of the Company shall be equal to the average closing price of a share of Common Stock of the Company reported for the twenty (20) day trading period ending on the date immediately prior to the date on which the Holder delivers its Notice of Exercise to the Company. If the Common Stock of the Company is not regularly traded in a public market, the Board of Directors of the Company shall determine, in its reasonable good faith judgment, the fair market value of a share of Common Stock of the Company as of the date immediately prior to the date on which the Holder delivers its Notice of Exercise to the Company. In the event that the Holder elects to exercise less than the full number of Shares recorded above, the Company will execute and deliver to the Holder a Warrant of like tenor in the number of Shares granted by the Company less the number of Shares exercised.
REGEN BIOLOGICS, INC. NONQUALIFIED STOCK OPTION AGREEMENTNonqualified Stock Option Agreement • March 27th, 2008 • Regen Biologics Inc • Surgical & medical instruments & apparatus • Delaware
This Nonqualified Stock Option Agreement (this “Agreement”), dated as of the Grant Date set forth below, is by and between ReGen Biologics, Inc., a Delaware corporation (the “Corporation”), and the non-employee director of the Corporation or its subsidiary identified below (the “Optionee”).
REGEN BIOLOGICS, INC. NONQUALIFIED STOCK OPTION AGREEMENTNonqualified Stock Option Agreement • March 27th, 2008 • Regen Biologics Inc • Surgical & medical instruments & apparatus • Delaware
This Nonqualified Stock Option Agreement (this “Agreement”), dated as of the Grant Date set forth below, is by and between ReGen Biologics, Inc., a Delaware corporation (the “Corporation”), and the employee or consultant of the Corporation or its subsidiary identified below (the “Optionee”).
